Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women

Abstract

BACKGROUND: Pre-Exposure Prophylaxis (PrEP) use has remained low among US women while significantly increasing among men who have sex with men. Besides lack of awareness, women face several social and structural barriers in gaining access to and using PrEP. METHODS: Four focus group discussions with 20 HIV-negative women who live in the Washington DC metropolitan area. RESULTS: The women expressed concerns about social and structural barriers to PrEP use. They were afraid that stigma related to using "HIV medicines" could affect PrEP use as well. They are worried that family and friends may question their reasons for taking anti-retrovirals and suspect that they were HIV-positive. They expected hostile reactions from male partners, including accusations of infidelity and introducing mistrust in their relationships. Communicating with health care providers about sexual matters in general and their need for PrEP in particular were identified as further barriers. Women reported that providers rarely ask about risk behaviors related to HIV acquisition; that short visits hinder establishing a trusting relationship to discuss sensitive matters. They were concerned that disclosure of risk behaviors may result in judgmental responses and harsh treatment from providers. Lastly, women were concerned that PrEP costs, including insurance coverage and copays, would keep PrEP out of their reach. While cognizant of the potential barriers, women were unwavering in their determination to find ways to circumvent challenges to PrEP access. CONCLUSION: Social and structural barriers may impede women's access to PrEP despite their own reported interest. Continued efforts to reduce HIV stigma, improve patient-provider relationships and ensure affordability of PrEP may increase the likelihood that women will use this important prevention modality.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 40

1. 1.

   Interim guidance: Pre-exposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.

   Not in our library

2. 2.

   Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2011;61:586-589.

   Not in our library

3. 3.

   Food and Drug Administration. FDA approves first drug for reducing the risk of prophylaxis for HIV prevention in heterosexual men and women. 2012.

   Not in our library

4. 4.

   Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.

   Not in our library10.1056/nejmoa1108524

5. 5.

   Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.

   Not in our library10.1056/nejmoa1011205

6. 6.

   Volk JE, Marcus JK, Phengrasamy T, Blechinger D, Nguyen DP, et al. No new HIV infections with increasing use of HIV pre-exposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61:1601-1613.

   Not in our library10.1093/cid/civ778

7. 7.

   HIV among women. CDC. 2016.

   Not in our library

8. 8.

   Bush S. Racial characteristics of FTC/TDF for pre-exposure prophylaxis users in the U.S. Presentation of the American Society for Microbiology. 2016.

   Not in our library

9. 9.

   Jayakumaran JS, Aaron E, Gracely EJ, Schriver E, Szep Z, et al. Knowledge, attitudes and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS ONE. 2016;11:1-10.

   Not in our library10.1371/journal.pone.0145670

10. 10.

    Goparaju L, Experton LS, Praschan NC, Warren-Jeanpiere L, Young MA, et al. Women want pre-exposure prophylaxis but are advised against it by their HIV-positive counterparts. J AIDS Clin Res. 2015;6:1-10.

    Not in our library10.4172/2155-6113.1000522

11. 11.

    Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29:102-110.

    Not in our library10.1089/apc.2014.0142

12. 12.

    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-518.

    Not in our library10.1056/nejmoa1402269

13. 13.

    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.

    Not in our library10.1056/nejmoa1202614

14. 14.

    Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, et al. FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defc Syndr. 2014;66:324-331.

    Not in our library10.1097/qai.0000000000000158

15. 15.

    Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:1-8.

    Not in our library10.1126/scitranslmed.3003174

16. 16.

    van der Straten A, Mayo A, Brown ER, Rivet Amico K, Cheng H, et al. Perceptions and experiences with the VOICE adherence strengthening program (VASP) in the MTN-003 trial. AIDS Behav. 2015;19:770-783.

    Not in our library10.1007/s10461-014-0945-2

17. 17.

    van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;7:1-7.

    Not in our library10.7448/ias.17.3.19146

18. 18.
    Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study · 2012

    No notice
19. 19.

    Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R, et al. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24:408-421.

    Not in our library10.1521/aeap.2012.24.5.408

20. 20.
    How Acceptable are Antiretrovirals for the Prevention of Sexually Transmitted HIV?: A Review of Research on the Acceptability of Oral Pre-exposure Prophylaxis and Treatment as Prevention · 2013

    No notice
21. 21.

    Roberts ET, Matthews DD. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Soc Sci Med. 2012;75:1555-1561.

    Not in our library10.1016/j.socscimed.2012.02.016

22. 22.

    Cowan FM, Delany-Moretlwe S. Promise and pitfalls of pre-exposure prophylaxis for female sex workers. Curr Opin HIV AIDS. 2016;11:27-34.

    Not in our library10.1097/coh.0000000000000215

23. 23.

    Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59:463-468.

    Not in our library10.1097/qai.0b013e31824a060b

24. 24.

    Brody LR, Jack DC, Bruck-Segal DL, Ruffing EG, Firpo-Perretti YM, et al. Life lessons from women with HIV: Mutuality, self-awareness and self-efficacy. AIDS Patient Care STDS. 2016;30:261-73.

    Not in our library10.1089/apc.2016.0031

25. 25.

    Bacon MC, Wyl VV, Alden C, Sharp G, Robison E, et al. The Women's interagency HIV study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019.

    Not in our library10.1128/cdli.12.9.1013-1019.2005

26. 26.

    Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States, in a clinical practice guideline. 2014.

    Not in our library

27. 27.

    Basic information on PrEP: Fact sheet. 2015.

    Not in our library

28. 28.

    Mahajan AP, Sayles JN, Patel VA, Remien RH, Ortiz D, et al. Stigma in the HIV/AIDS epidemic: A review of the literature and recommendations for the way forward. AIDS. 2008;22:67-79.

    Not in our library10.1097/01.aids.0000327438.13291.62

29. 29.

    Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav. 2006;10:473-482.

    Not in our library10.1007/s10461-006-9099-1

30. 30.

    Montgomery ET, Straten AV, Chidanyika A, Chipato T, Jaffar S, et al. The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011;15:959-969.

    Not in our library10.1007/s10461-010-9806-9

31. 31.

    Braksmajer A, Senn TE, McMahon J. The Potential of pre-exposure prophylaxis for women in violent relationships. AIDS Patient Care STDS. 2016;30:274-281.

    Not in our library10.1089/apc.2016.0098

32. 32.

    Brothers J, Hotton AL, Hosek SG, Harper GW, Fernandez I. Young women living with HIV: Outcomes from a targeted secondary prevention empowerment pilot trial. AIDS Patient Care STDS. 2016;30:229-235.

    Not in our library10.1089/apc.2015.0294

33. 33.

    Loeb DF, Lee RS, Binswanger IA, Ellison MC, Aagaard EM. Patient, resident physician and visit factors associated with documentation of sexual history in the outpatient setting. J Gen Intern Med. 2011;26:887-893.

    Not in our library10.1007/s11606-011-1711-z

34. 34.

    Wimberly YH, Hogben M, Moore-Ruffin J, Moore SE, Fry-Johnson Y. Sexual history-taking among primary care physicians. J Natl Med Assoc. 2006;98:1924-1929.

    Not in our library

35. 35.

    Lanier Y, Castellanos T, Barrow RY, Jordan WC, Caine V, et al. Brief sexual histories and routine HIV/STD testing by medical providers. AIDS Patient Care STDS. 2014;28:113-120.

    Not in our library10.1089/apc.2013.0328

36. 36.

    Flickinger TE, Berry S, Korthuis PT, Saha S, Laws MB, et al. Counseling to reduce high-risk sexual behavior in HIV care: A multi-center, direct observation study. AIDS Patient Care STDS. 2013;27:416-424.

    Not in our library10.1089/apc.2012.0426

37. 37.

    Ngure K, Heffron R, Curran K, Vusha S, et al. I knew i would be safer. Experiences of Kenyan HIV serodiscordant couples soon after pre-exposure prophylaxis (PrEP) initiation. AIDS Patient Care STDS. 2016;30:78-83.

    Not in our library10.1089/apc.2015.0259

38. 38.

    Muessig KE, Panter AT, Mouw MS, Amola K, et al. Medication-taking practices of patients on antiretroviral HIV therapy: Control, power and intentionality. AIDS Patient Care STDS. 2015;29:606-616.

    Not in our library10.1089/apc.2015.0058

39. 39.

    Rubtsova A, Wingoof GM, Dunkle K, Camp C, DiClemente RJ. Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): Results of a national survey. Curr HIV Res. 2013;11:543-548.

    Not in our library10.2174/1570162x12666140129104952

40. 40.

    Finocchario-Kessler S, Champassak S, Hoyt MJ, Short W, Rana C, et al. Pre-exposure prophylaxis (PrEP) for safer conception among serodifferent couples: Findings from healthcare providers serving patients with HIV in seven US cities. AIDS Patient Care STDS. 2016;30:125-133.

    Not in our library10.1089/apc.2015.0268

Cited by papers we hold 4

• Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis · 2024
  No notice
• Where’s the “Everyday Black Woman”? An intersectional qualitative analysis of Black Women’s decision-making regarding HIV pre-exposure prophylaxis (PrEP) in Mississippi · 2022
  Not checked
• “PrEP’s just to secure you like insurance”: a qualitative study on HIV pre-exposure prophylaxis (PrEP) adherence and retention among black cisgender women in Mississippi · 2021
  Not checked
• The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.